Navigation Links
Apnex Medical, Inc. Receives FDA Approval for Pivotal Clinical Study for Obstructive Sleep Apnea
Date:8/2/2011

ST. PAUL, Minn., Aug. 2, 2011 /PRNewswire/ -- Apnex Medical, Inc., received investigational device exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to begin a clinical study to evaluate the safety and effectiveness of its Hypoglossal Nerve Stimulation (HGNS®) System to treat obstructive sleep apnea (OSA). Data from this clinical study are intended to support the Pre-Market Approval (PMA) application for the HGNS System to the FDA.

"Many patients who suffer from OSA are unable to tolerate existing therapies such as continuous positive airway pressure (CPAP). The HGNS System provides a fundamentally new approach to the treatment of OSA. This study will help us further understand the potential role this device will have in treating the millions of people who suffer from OSA," said the study's co-principal investigator, Dr. Atul Malhotra, Clinical Chief, Division of Sleep Medicine, Brigham and Women's Hospital.

Sponsored by Apnex Medical, the Apnex Clinical Study is a prospective, randomized, multi-center clinical trial. It is being conducted in leading medical centers in the United States, Europe and Australia. The trial is designed to demonstrate the safety and effectiveness of the HGNS therapy in treating patients with moderate to severe OSA. To be enrolled in the study patients must not have received lasting benefit from CPAP or other OSA treatments.

"We have seen very encouraging results from the HGNS feasibility studies. Results recently presented at the international SLEEP meeting showed that most patients treated with the HGNS System experienced significant improvements in their sleep apnea, sleepiness, and quality of life. This study will help us determine if these results can be demonstrated in a second larger patient population," said the study's co-principal investigator, Dr. Eric Kezirian, Department of Otolaryngology – Head and Neck Surgery, University of California, San Francisco.

About Apnex Medical, Inc. and HGNS System

Apnex Medical was founded in 2006 with a mission to pioneer medical innovations to improve the health of people with sleep disordered breathing. The company has developed a proprietary medical device for the treatment of OSA.

The Apnex HGNS System is an implantable therapy that is intended to work by activating the muscles in the upper airway to ensure that the airway remains open during sleep. The system detects the patient's breathing and delivers mild stimulation to the hypoglossal nerve, the nerve that controls the muscles of the tongue, to keep the airway open. The stimulation is timed to a patient's own breathing pattern. The HGNS System is designed to work only when the patient is asleep through a handheld controller.

About OSA

According to the World Health Organization approximately 100 million people worldwide have OSA. It occurs because of blockage of breathing during sleep. This can deprive OSA sufferers of deep restful sleep and lead to sleepiness and fatigue. OSA sufferers are also at an increased risk for a variety of health conditions, including high blood pressure, coronary artery disease, diabetes and stroke. Untreated OSA is also associated with an increased risk of death. Current OSA treatments are not always successful or well tolerated. The Apnex device is designed to provide an alternative treatment for OSA that addresses these problems.

More information on the Apnex Clinical Study can be found at www.SleepApneaTrial.com. To learn if you might qualify for the study go to this website or call 1-888-975-3370.

To request additional information, please contact:

Apnex Medical, Inc.
2890 Centre Pointe Drive
St. Paul, MN 55113 USA
+1.651.757.4300
www.apnexmedical.com

CAUTION: The Apnex HGNS System is an investigational device and is limited by Federal Law to investigational use.

FOR CLINICAL TRIAL USE ONLY.

Apnex Medical, Apnex and HGNS are registered trademarks of Apnex Medical, Inc.

© Apnex Medical, Inc. 2011 All rights reserved.


'/>"/>
SOURCE Apnex Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Apnex Medical, Inc. Raises Additional $14 Million
2. Apnex Medical, Inc. Names Chas McKhann President, Chief Executive Officer
3. Prescient Medical, Inc. Acquires New Technology to Detect Inflammation in Coronary Blood Vessels
4. Prescient Medical, Inc. Achieves Successful Clinical Debut of vProtect(TM) Luminal Shield
5. China Sky One Medical, Inc. Announces 26 New Drugs in Clinical Trials
6. China Sky One Medical, Inc. Achieves Significant Breakthrough in Research for Sudden Cardiac Death (SCD) Early Examination Kit
7. New Study Shows that Prebiotics, as Used by Jackson GI Medical, Increases Lifespan by 33%
8. Luminous Medical, Inc. Secures Exclusive Rights to Glucose Sensor for Its Automated Glucose Monitor
9. Cardiva Medical, Inc. Announces the Departure of its President and his Appointment as CEO of Innovative Energy, Inc.
10. Tenaxis Medical, Inc. Announces Completion of the Enrollment Phase of Their Pivotal Study
11. China Sky One Medical, Inc. Completes and Moves into New Corporate Headquarters
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... March 30, 2017  Lannett Company, Inc. (NYSE: ... made a $25 million payment against its existing revolving ... combined with the $75 million payment we made earlier ... million in annualized cash interest expense, at current rates" ... Lannett.  "Our business is solid and we continue to ...
(Date:3/30/2017)... March 30, 2017 Revenue Prospects by Product ... and COPD) and Geography Respiratory Inhalers - our new ... the Respiratory Inhalers market heading? If you are involved in this ... report shows you the potential revenues streams to 2027, assessing data, ... ...
(Date:3/30/2017)... Julie & Lefkowitz LLP, a class action law firm dedicated ... fiduciary duty claim involving the board of directors of Synergy ... If you are a shareholder of Synergy Pharmaceuticals and are ... charge, please visit us at: ... http://pjlfirm.com/synergy-pharmaceuticals-inc/ ...
Breaking Medicine Technology:
(Date:3/30/2017)... (PRWEB) , ... March 30, 2017 , ... ... is expanding its educational offerings of corporate finance programs to address the increasingly ... program, will help executives increase their knowledge of sophisticated corporate finance and will ...
(Date:3/30/2017)... ... March 30, 2017 , ... ... Academy of Nutrition and Dietetics (AND), will join nonprofit Seafood Nutrition Partnership (SNP) ... a live webinar designed to help nutrition educators and students inform consumers about ...
(Date:3/29/2017)... ... March 29, 2017 , ... During the last week ... free screening colonoscopies to eligible individuals in the local community. , Colon cancer ... regular screenings can detect colon cancer while it is small, confined and easier to ...
(Date:3/29/2017)... NY (PRWEB) , ... March 29, 2017 , ... ... men’s and women’s professional squash, announced it has enlisted New York City-based sports ... The agency will develop and procure sponsorship opportunities for the Professional Squash Association ...
(Date:3/29/2017)... ... ... CHARM CITY RUN WELCOMES MERCY MEDICAL CENTER AS , BALTIMORE WOMEN’S CLASSIC TITLE ... the official title sponsor of the Baltimore Women’s Classic, the largest all women’s 5K ... walk or run the course around the Baltimore Inner Harbor. Mercy has been the ...
Breaking Medicine News(10 mins):